Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD PICO 4: In patients with T2D and either atherosclerotic CVD (ASCVD) or high CV risk, what is the role of novel anti-hyperglycemic agents compared with placebo for reduction of a composite of CV death, nonfatal MI, or nonfatal stroke
Zepbound (tirzepatide) weekly injection dosing schedule The weekly dosing schedule of Zepboud is as follows: Weeks 1-4 (starting dose): 2.5 mg once weekly for the first 4 weeks Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly Weeks 13-16 : If tolerated, increase to 10 mg once weekly Weeks 17-20: If the dosage needs to be escalated further, increase to 12.5 mg once weekly for 4 weeks Weeks 21 and onward : If the previous dose is ineffective, the next dose will be 15 mg once weekly
Key Strategies Adopted by Players 6.1.3
Overall, this experience was expensive, unsatisfactory and ultimately useless
Em caso de dvida, consulta o teu mdico ou profissional de sade